The activation of the RAS-RAF-MEK-ERK signaling pathway as a consequence of KRAS mutations renders it an attractive target for small-molecule inhibition in KRAS-mutated NSCLC. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.